.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Naproxen - Generic Drug Details

« Back to Dashboard
Naproxen is the generic ingredient in eleven branded drugs marketed by Teva, Dava Pharms Inc, Invagen Pharms, Teva Pharms, Hamilton Pharms, Ivax Sub Teva Pharms, Roxane, Marksans Pharma, Zydus Pharms Usa, Mylan, Amneal Pharms Ny, Aurobindo Pharma Usa, Actavis Elizabeth, Pliva, Perrigo R And D, Sandoz, Glenmark Generics, Watson Labs, Purepac Pharm, Atnahs Pharma Us, Mylan Pharms Inc, Hikma Intl Pharms, Bayer, Actavis Labs Fl Inc, Bionpharma Inc, Aurobindo Pharma Ltd, Contract Pharmacal, Able, Alvogen Malta, Granules India, Perrigo, Dr Reddys Labs Inc, Hikma, Sun Pharm Inds Ltd, Dr Reddys Labs Ltd, and Pernix Ireland Ltd, and is included in seventy-one NDAs. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are forty-two drug master file entries for naproxen. Seventy suppliers are listed for this compound.

Summary for Generic Name: naproxen

Tradenames:11
Patents:5
Applicants:36
NDAs:71
Drug Master File Entries: see list42
Suppliers / Packaging: see list70
Therapeutic Class:Analgesics
Anti-inflammatory Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices

Pharmacology for Ingredient: naproxen

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Contract Pharmacal
NAPROXEN SODIUM
naproxen sodium
TABLET;ORAL074635-001Jan 13, 1997OTCNo► subscribe► subscribe
Pliva
NAPROXEN
naproxen
TABLET, DELAYED RELEASE;ORAL075337-002May 26, 1999RXNo► subscribe► subscribe
Marksans Pharma
NAPROXEN
naproxen
TABLET;ORAL091416-001Feb 14, 2011RXNo► subscribe► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: naproxen

These historical archives are available as an add-on to one-year subscriptions.
See the Subscription Options for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Atnahs Pharma Us
NAPROSYN
naproxen
TABLET;ORAL017581-004Apr 15, 19823,998,966► subscribe
Atnahs Pharma Us
NAPROSYN
naproxen
TABLET;ORAL017581-003Approved Prior to Jan 1, 19824,001,301► subscribe
Atnahs Pharma Us
NAPROSYN
naproxen
TABLET;ORAL017581-003Approved Prior to Jan 1, 19824,009,197► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc